Billiontoone (NASDAQ:BLLN – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.06), Zacks reports.
Billiontoone Stock Up 4.7%
Billiontoone stock traded up $4.87 during midday trading on Tuesday, reaching $109.53. The stock had a trading volume of 201,121 shares, compared to its average volume of 201,169. Billiontoone has a twelve month low of $88.00 and a twelve month high of $138.70.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on BLLN shares. BTIG Research began coverage on shares of Billiontoone in a report on Monday, December 1st. They set a “buy” rating and a $160.00 price target on the stock. Wall Street Zen upgraded Billiontoone to a “hold” rating in a research report on Saturday, November 15th. William Blair initiated coverage on Billiontoone in a report on Monday, December 1st. They issued an “outperform” rating for the company. Piper Sandler began coverage on Billiontoone in a research report on Monday, December 1st. They issued an “overweight” rating and a $150.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on shares of Billiontoone in a research note on Monday, December 1st. They issued a “buy” rating and a $145.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $138.67.
About Billiontoone
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule.
See Also
- Five stocks we like better than Billiontoone
- 5 discounted opportunities for dividend growth investors
- Office Suite Gets Pricier: Microsoft’s Bold Move Comes With Risk
- What is a support level?
- Big Blue’s Big Bet: IBM Buys AI Nervous System for $11B
- What is the Dogs of the Dow Strategy? Overview and Examples
- Carvana Soars Over 10,000% From Lows—Now It’s in the S&P 500
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
